BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 2093017)

  • 1. The clinical safety of omeprazole.
    Sölvell L
    Digestion; 1990; 47 Suppl 1():59-63; discussion 76. PubMed ID: 2093017
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical safety of omeprazole.
    Sölvell L
    Scand J Gastroenterol Suppl; 1989; 166():106-10; discussion 111-3. PubMed ID: 2690327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of Zollinger-Ellison syndrome and omeprazole therapy on gastric oxyntic endocrine cells.
    Maton PN; Lack EE; Collen MJ; Cornelius MJ; David E; Gardner JD; Jensen RT
    Gastroenterology; 1990 Oct; 99(4):943-50. PubMed ID: 1697548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study.
    Maton PN; Vinayek R; Frucht H; McArthur KA; Miller LS; Saeed ZA; Gardner JD; Jensen RT
    Gastroenterology; 1989 Oct; 97(4):827-36. PubMed ID: 2777040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical experience with omeprazole: assessment of efficacy and safety.
    Walan A
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():27-33. PubMed ID: 2491359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers.
    Meijer JL; Jansen JB; Lamers CB
    Digestion; 1989; 44 Suppl 1():31-9. PubMed ID: 2575060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric endocrine cells in omeprazole-treated and untreated patients with the Zollinger-Ellison syndrome.
    Bardram L; Thomsen P; Stadil F
    Digestion; 1986; 35 Suppl 1():116-22. PubMed ID: 3792668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of patients with Zollinger-Ellison syndrome.
    Mignon M; Pospai D; Forestier S; Vatier J; Vallot T
    Clin Ther; 1993; 15 Suppl B():22-31. PubMed ID: 8205592
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omeprazole in the Zollinger-Ellison syndrome.
    Bardram L; Stadil F
    Scand J Gastroenterol; 1986 Apr; 21(3):374-8. PubMed ID: 3715402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility and safety of omeprazole.
    Walan A
    Methods Find Exp Clin Pharmacol; 1989; 11 Suppl 1():107-11. PubMed ID: 2657279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omeprazole in Zollinger-Ellison syndrome. Effects of a single dose and of long-term treatment in patients resistant to histamine H2-receptor antagonists.
    Lambers CB; Lind T; Moberg S; Jansen JB; Olbe L
    N Engl J Med; 1984 Mar; 310(12):758-61. PubMed ID: 6142418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of omeprazole in patients with Zollinger-Ellison syndrome.
    Frucht H; Maton PN; Jensen RT
    Dig Dis Sci; 1991 Apr; 36(4):394-404. PubMed ID: 2007355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Omeprazole in the therapy of acid-induced diseases].
    Simon B; Dammann HG; Müller P
    Z Gastroenterol; 1987 Aug; 25 Suppl 3():146-51. PubMed ID: 2889299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Omeprazole in acute and long-term treatment of Asian patients with peptic ulcer refractory to H2-antagonists.
    Chelvam P; Wong EC
    J Gastroenterol Hepatol; 1989; 4 Suppl 2():75-81. PubMed ID: 2577478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxyntic mucosa histology in omeprazole-treated patients suffering from duodenal ulcer or Zollinger-Ellison syndrome.
    Helander HF
    Digestion; 1986; 35 Suppl 1():123-9. PubMed ID: 3792669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Omeprazole and peptic ulcer. Profile of a new active agent].
    Müller P; Dammann HG; Simon B
    Fortschr Med; 1987 Jan; 105(2):35-8. PubMed ID: 3557254
    [No Abstract]   [Full Text] [Related]  

  • 17. [Anti-H2 and omeprazole in brief therapy of peptic ulcer].
    Piai G; Sabbatini F; Mazzacca G
    Ann Ital Chir; 1990; 61(1):11-4. PubMed ID: 1978622
    [No Abstract]   [Full Text] [Related]  

  • 18. Safety experience from long-term treatment with omeprazole.
    Joelson S; Joelson IB; Lundborg P; Walan A; Wallander MA
    Digestion; 1992; 51 Suppl 1():93-101. PubMed ID: 1397750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risk for developing tumors in therapy with the proton pump inhibitor omeprazole].
    Eissele R; Arnold R
    Versicherungsmedizin; 1993 Aug; 45(4):126-9. PubMed ID: 8379045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medical treatment of peptic ulcers.
    Deveney CW; Deveney KE
    Surg Annu; 1985; 17():219-33. PubMed ID: 3883541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.